Ardelyx Bets Big On Tenapanor’s Potential, Despite Side Effect Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Unwinding NHE3 partnership with AstraZeneca, Ardelyx plans to move first-in-class agent into Phase III in IBS-C while seeking more tolerable dosing regimen for late-stage development in hyperphosphatasia.